FDA Grants Breakthrough Therapy Designation to VER-01, First-in-Class Cannabis-Based Treatment for Chronic Low Back Pain
核心洞察
The FDA has granted Breakthrough Therapy Designation to VER-01, VERTANICAL (搜索)'s first-in-class non-opioid investigational treatment for chronic low back pain (搜索), following positive Phase 3 trial results.
Two randomized Phase 3 trials demonstrated VER-01's significant pain reduction, favorable tolerability profile, and superior performance compared to opioids (搜索) with better gastrointestinal tolerability.
VER-01 is a standardized full-spectrum extract from Cannabis sativa strain DKJ127 L., designed specifically for chronic pain (搜索) management with no evidence of dependence or withdrawal symptoms.
VERTANICAL (搜索) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, the company's first-in-class non-opioid investigational treatment for chronic low back pain (搜索). The designation follows two randomized, controlled Phase 3 trials that demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of investigational medicines where preliminary clinical evidence indicates the potential for substantial improvement over available therapies. For VERTANICAL (搜索), the designation represents an important regulatory milestone in its U.S. development program and underscores the potential of VER-01 in a therapeutic area where meaningful innovation has remained limited for decades.
Addressing Critical Unmet Medical Need
Chronic pain (搜索) remains one of the largest unmet needs in healthcare, affecting more than one billion people worldwide, including more than 60 million Americans. For many patients, opioids (搜索) remain central in pain management despite well-documented risks, including dependence, abuse potential and debilitating side effects.
The need for effective, well-tolerated non-opioid treatment options remains especially urgent in the United States. Despite its enormous medical, social, and economic burden, innovation in chronic pain (搜索) treatment has substantially lagged behind other major disease areas. With its novel mechanism of action, VER-01 represents a differentiated investigational approach in a field still shaped by long-standing treatment paradigms.
"The FDA's Breakthrough Therapy Designation for VER-01 is a major recognition of its potential to address the significant unmet need in chronic pain (搜索)," said Dr. Clemens Fischer, CEO of FUTRUE Group (搜索) and Founder of VERTANICAL (搜索). "Patients have waited far too long for meaningful progress. We believe VER-01 has the potential to change how chronic pain is treated and offer physicians a much-needed non-opioid solution."
Phase 3 Clinical Trial Results
The designation is supported by results from VERTANICAL (搜索)'s European Phase 3 clinical program in chronic low back pain (搜索). In a placebo-controlled Phase 3 study published last September in Nature Medicine, VER-01 demonstrated significant reductions in pain compared with placebo and met the study's primary endpoint, with effects sustained during long-term treatment. Patients receiving VER-01 also experienced significant improvements in key symptoms associated with chronic pain (搜索), including sleep disturbances and impaired physical function.
In a second Phase 3 head-to-head comparator study, VER-01 demonstrated greater pain reduction and better gastrointestinal tolerability compared with opioids (搜索). Across the clinical program, VER-01 was generally well tolerated, with no evidence of dependence or withdrawal symptoms observed.
U.S. Development Program and Timeline
As VERTANICAL (搜索) expects marketing authorization in the first European countries in the coming weeks, the company has also initiated an additional pivotal Phase 3 trial in the United States to support a future FDA submission. The study is designed to confirm the efficacy and safety of VER-01 in U.S. patients with chronic low back pain (搜索) to address U.S. regulatory requirements.
Based on the current development plan, the company anticipates a first data read-out in 2027 and, subject to positive results, plans to submit a New Drug Application in 2028.
Standardized Cannabis-Based Formulation
VER-01 is an investigational standardized full-spectrum extract derived from the Cannabis sativa strain DKJ127 L., a unique and proprietary plant genetics selected to provide a phytochemical profile tailored to chronic pain (搜索). Its composition includes a defined mixture of cannabinoids, terpenes and other bioactive compounds selected for their potential relevance in pain modulation and associated symptoms.
VER-01 has been comprehensively characterized using chromatographic and spectrometric methods to quantify key constituents and ensure pharmaceutical-grade quality and product consistency. This level of standardization is critical, as cannabis-derived products differ substantially in their pharmacological profile, composition of bioactive constituents and product quality, depending on plant genetics, raw materials and manufacturing processes. Findings obtained with VER-01 can therefore not be extrapolated to other cannabis extracts or products.
VERTANICAL (搜索) was founded in 2007 by Dr. Clemens Fischer and has its global headquarters in Munich, Germany. The company operates one of the world's most advanced GMP facilities for the development and manufacturing of biopharmaceuticals and maintains an international network of several hundred research and clinical trial sites across the U.S. and multiple European countries.